Artio closes $28M as it scales to save lives; latest funding brings Prairie Village startup’s investments to $74M
June 16, 2022 | Startland News Staff
Another hefty funding round for Artio Medical is expected to launch the startup’s commercial sales team in the U.S. and continue development of its best-in-class product pipeline, said founder Nicholas Franano.
Artio, a medical device company developing innovative products for the peripheral vascular, neurovascular, and cardiology markets, on Thursday announced the closing of $28 million in oversubscribed Series A2 and Series A3 financing, bringing the total amount raised to date to $74 million.
Funds will be used to support U.S. commercialization efforts for the recently cleared Solus Gold Embolization Device and to accelerate the development of Artio’s broad portfolio of products, including expanding the company’s engineering and manufacturing capabilities, Franano said in a press release.
Click here to read more about Artio’s $12 million funding infusion in 2021.
“We would like to thank our existing investors for their continued strong support and also welcome a new group of investors to Artio,” said Joseph McConnell, vice president of finance and business operations at Artio.
“We have the opportunity to do something really special here, to bring a new generation of medical devices to market with the potential to save lives, reduce disability, and improve the quality of life for millions of people,” McConnell continued. “This new capital will help Artio expand our team and scale our operations to deliver on that mission.”
Artio is currently developing ten products for the peripheral vascular market, including the Solus Gold and Solus Flex Embolization Devices for peripheral vessel occlusion and the Amplifi Vein Dilation System which is designed to prepare hemodialysis patients for successful arteriovenous fistula vascular access site creation.
Artio is also currently developing four products for the neurovascular market, including the Endura Embolization System comprising a detachable balloon and coils for the treatment of saccular brain aneurysms.
Click here to learn more about Artio’s portfolio of products.
2022 Startups to Watch
stats here
Related Posts on Startland News
Hunting unicorns: C2FO spotlighted as startup likely to reach $1B valuation
Leawood-based C2FO is among the nation’s highest-momentum startups, according to CB Insights and The New York Times, which teamed up to name 50 “future unicorns.” The U.S. companies on the list — which analysts involved predict will eventually be valued at $1 billion or more — largely are based on the coasts. Twenty-two are in…
Thou Mayest sprouts fresh coffee concept in the suburbs; new Crossroads flagship percolating
Coffee needn’t be melancholy or monochromatic, said Thou Mayest founder Bo Nelson, bathed in warm sunlight at Cafe Equinox. “We have to wake people up,” said Nelson. “We’re trying to celebrate the diversity of life — humanity, plants, music, art — so many collisions. It’s not a distraction. It’s not a means to an end.…
Atonix Digital using predictive analytics to tackle Black & Veatch first, then the world
Black & Veatch offshoot Atonix Digital is re-engineering the future of its parent company’s customer base, said Paul McRoberts. Developed to offer software solutions to customers from Black & Veatch’s existing market sectors — power, water, and telecommunications — Atonix has the opportunity to move beyond its specific corporate origins to service other industries, said…
K-State institute’s expanded focus: Boost Kansas companies launching new tech
Every Startup A Wildcat? The Technology Development Institute at Kansas State University is evolving its role and services to improve the economic competitiveness of Kansas companies. Broadening activity at the institute — formerly known as the Advanced Manufacturing Institute — reflects a focus on developing, protecting and launching new technologies for a range of partners,…